CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Oct. 31, 2013	Oct. 31, 2012
Cash flows from operating activities
Net income	$ 63,728	$ 48,672
Adjustments to reconcile net income to net cash used in operating activities:
Depreciation and amortization	9,523	6,964
Equity based compensation	6,826	4,493
Tax benefit from exercise/vesting of equity awards	4,639	1,261
Deferred financing charges	565	280
Equity loss in joint venture		706
Gain on sale of joint venture interest		(185)
Changes in operating assets and liabilities:
Accounts receivable, net	(219,198)	(193,181)
Inventories	(42,238)	(44,005)
Income taxes, net	18,727	21,358
Prepaid expenses and other current assets	3,031	(1,742)
Other assets, net	(10,628)	(3,791)
Accounts payable, accrued expenses and other liabilities	28,849	18,911
Net cash used in operating activities	(136,176)	(140,259)
Cash flows from investing activities
Acquisition of Vilebrequin, net of cash acquired		(80,252)
Proceeds from equity of joint venture, net		1,898
Capital expenditures	(15,714)	(6,992)
Net cash used in investing activities	(15,714)	(85,346)
Cash flows from financing activities
Proceeds from notes payable, net	150,781	235,042
Noncontrolling interest investment, net	1,905	2,309
Proceeds from exercise of equity awards	1,016	1,182
Excess tax benefit from exercise/vesting of equity awards	2,526	1,720
Taxes paid for net share settlement	(1,005)
Net cash provided by financing activities	155,223	240,253
Effect of exchange rate changes	(882)	338
Net increase in cash and cash equivalents	2,451	14,986
Cash and cash equivalents at beginning of period	27,360	24,660
Cash and cash equivalents at end of period	29,811	39,646
Cash paid during the period for:
Interest	6,120	7,794
Income taxes	$ 15,445	$ 4,867